Literature DB >> 24013190

An LC-MS assay for the screening of cardiovascular medications in human samples.

Eduardo Dias1, Brian Hachey, Candace McNaughton, Hui Nian, Chang Yu, Brittany Straka, Nancy J Brown, Richard M Caprioli.   

Abstract

Cardiovascular drugs are the most commonly prescribed medications. Some prior assays successfully detect cardiovascular drugs among multiple classes using a single sample. Here, we develop an assay to detect a broad range of cardiovascular drug classes to include commonly used cardiovascular drugs and evaluate the assay's analytical and statistical properties in a clinical setting. We describe a protocol for drug detection that encompasses 34 commonly prescribed cardiovascular drugs or drug metabolites with a single LC-MS/MS method using 100μL of serum or plasma. Drug classes monitored by this assay include: anticoagulants, angiotensin converting enzyme inhibitors (ACEI), angiotensin II receptor blockers (ARB), beta blockers, calcium channel blockers, diuretics, statins, and vasodilators, as well as digoxin, fenofibrate, and niacin. Analytical accuracy and precision for each drug were evaluated by repeating the assay on spiked samples at low, medium, and high concentrations. In 294 clinical samples obtained from hospitalized patients for whom medication administration was recorded, we evaluated the assay's statistical sensitivity, specificity, and accuracy. For the 34 drugs or drug metabolites, the assay was statistically sensitive (>0.90) for all drugs except captopril (0.25), isosorbide (0.81), and niacin (0.89). The assay was statistically specific for all drugs, with a minimum specificity of 0.94 (aspirin). To our knowledge, this method is the first method of simultaneous analysis of 34 cardiovascular drugs or drug metabolites from nine drug classes evaluated using clinical samples from hospitalized patients.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cardiovascular drugs; Clinical samples; Drug monitoring; Liquid chromatography; Mass spectrometry; Selectivity

Mesh:

Substances:

Year:  2013        PMID: 24013190      PMCID: PMC3800555          DOI: 10.1016/j.jchromb.2013.08.010

Source DB:  PubMed          Journal:  J Chromatogr B Analyt Technol Biomed Life Sci        ISSN: 1570-0232            Impact factor:   3.205


  34 in total

1.  Development of a multi-target screening analysis for 301 drugs using a QTrap liquid chromatography/tandem mass spectrometry system and automated library searching.

Authors:  C A Mueller; W Weinmann; S Dresen; A Schreiber; M Gergov
Journal:  Rapid Commun Mass Spectrom       Date:  2005       Impact factor: 2.419

Review 2.  Adherence to medication.

Authors:  Lars Osterberg; Terrence Blaschke
Journal:  N Engl J Med       Date:  2005-08-04       Impact factor: 91.245

3.  Determination of fenofibric acid in human plasma by ultra performance liquid chromatography-electrospray ionization mass spectrometry: application to a bioequivalence study.

Authors:  Dasandi Bhavesh; Sanjay Shah
Journal:  Biomed Chromatogr       Date:  2009-09       Impact factor: 1.902

4.  Validation of a fast liquid chromatography-UV method for the analysis of drugs used in combined cardiovascular therapy in human plasma.

Authors:  Gorka Iriarte; Oskar Gonzalez; Nerea Ferreirós; Miren Itxaso Maguregui; Rosa Maria Alonso; Rosa Maria Jiménez
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2009-07-19       Impact factor: 3.205

5.  Optimization and validation of a SPE-HPLC-PDA-fluorescence method for the simultaneous determination of drugs used in combined cardiovascular therapy in human plasma.

Authors:  Oskar Gonzalez; Gorka Iriarte; Nerea Ferreirós; Miren Itxaso Maguregui; Rosa Maria Alonso; Rosa Maria Jiménez
Journal:  J Pharm Biomed Anal       Date:  2008-11-05       Impact factor: 3.935

6.  The comparative bioavailability of an extended-release niacin and lovastatin fixed dose combination tablet versus extended-release niacin tablet, lovastatin tablet and a combination of extended-release niacin tablet and lovastatin tablet.

Authors:  R Menon; D Tolbert; E Cefali
Journal:  Biopharm Drug Dispos       Date:  2007-09       Impact factor: 1.627

7.  Prevalence, predictors, and outcomes of primary nonadherence after acute myocardial infarction.

Authors:  Cynthia A Jackevicius; Ping Li; Jack V Tu
Journal:  Circulation       Date:  2008-02-26       Impact factor: 29.690

Review 8.  Clinical pharmacokinetics and pharmacodynamics of aliskiren.

Authors:  Sujata Vaidyanathan; Venkateswar Jarugula; Hans Armin Dieterich; Dan Howard; William P Dole
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

9.  Determination of clopidogrel main metabolite in plasma: a useful tool for monitoring therapy?

Authors:  Helen Mani; Stefan W Toennes; Birgit Linnemann; Dorota A Urbanek; Jan Schwonberg; Gerold F Kauert; Edelgard Lindhoff-Last
Journal:  Ther Drug Monit       Date:  2008-02       Impact factor: 3.681

Review 10.  Medication adherence: its importance in cardiovascular outcomes.

Authors:  P Michael Ho; Chris L Bryson; John S Rumsfeld
Journal:  Circulation       Date:  2009-06-16       Impact factor: 29.690

View more
  7 in total

1.  Systolic Blood Pressure and Biochemical Assessment of Adherence: A Cross-Sectional Analysis in the Emergency Department.

Authors:  Candace D McNaughton; Nancy J Brown; Russell L Rothman; Dandan Liu; Edmond K Kabagambe; Phillip D Levy; Wesley H Self; Alan B Storrow; Sean P Collins; Christianne L Roumie
Journal:  Hypertension       Date:  2017-06-26       Impact factor: 10.190

2.  Medication adherence, medical record accuracy, and medication exposure in real-world patients using comprehensive medication monitoring.

Authors:  Timothy P Ryan; Ryan D Morrison; Jeffrey J Sutherland; Stephen B Milne; Kendall A Ryan; J Scott Daniels; Anita Misra-Hebert; J Kevin Hicks; Eric Vogan; Kathryn Teng; Thomas M Daly
Journal:  PLoS One       Date:  2017-09-28       Impact factor: 3.240

3.  Text Messaging to Improve Hypertension Medication Adherence in African Americans From Primary Care and Emergency Department Settings: Results From Two Randomized Feasibility Studies.

Authors:  Lorraine Buis; Lindsey Hirzel; Rachelle M Dawood; Katee L Dawood; Lauren P Nichols; Nancy T Artinian; Loren Schwiebert; Hossein N Yarandi; Dana N Roberson; Melissa A Plegue; LynnMarie C Mango; Phillip D Levy
Journal:  JMIR Mhealth Uhealth       Date:  2017-02-01       Impact factor: 4.773

4.  Signal Enhancement in the HPLC-ESI-MS/MS analysis of spironolactone and its metabolites using HFIP and NH4F as eluent additives.

Authors:  Kalev Takkis; Rudolf Aro; Lenne-Triin Kõrgvee; Heili Varendi; Jana Lass; Koit Herodes; Karin Kipper
Journal:  Anal Bioanal Chem       Date:  2017-02-21       Impact factor: 4.142

Review 5.  Utility, promise, and limitations of liquid chromatography-mass spectrometry-based therapeutic drug monitoring in precision medicine.

Authors:  Vanessa P Gaspar; Sahar Ibrahim; René P Zahedi; Christoph H Borchers
Journal:  J Mass Spectrom       Date:  2021-11-04       Impact factor: 1.982

6.  Development, validation and application of a novel HPLC-MS/MS method for the quantification of atorvastatin, bisoprolol and clopidogrel in a large cardiovascular patient cohort.

Authors:  Richard Myles Turner; Vanessa Fontana; Mark Bayliss; Sarah Whalley; Anahi Santoyo Castelazo; Munir Pirmohamed
Journal:  J Pharm Biomed Anal       Date:  2018-07-03       Impact factor: 3.935

7.  Angiotensin-converting enzyme inhibitors increase anti-fibrotic biomarkers in African Americans with left ventricular hypertrophy.

Authors:  Cesar A Romero; Shobi Mathew; Benjamin Wasinski; Brian Reed; Aaron Brody; Rachelle Dawood; Michael J Twiner; Candace D McNaughton; Rafael Fridman; John M Flack; Oscar A Carretero; Phillip D Levy
Journal:  J Clin Hypertens (Greenwich)       Date:  2021-03-10       Impact factor: 3.738

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.